Venus Remedies edges up on getting gets product patent grant for Vancoplus

09 Feb 2015 Evaluate

Venus Remedies is currently trading at Rs. 179.30, up by 16.40 points or 10.07 % from its previous closing of Rs. 162.90 on the BSE.

The scrip opened at Rs. 160.65 and has touched a high and low of Rs. 182.50 and Rs. 155.10 respectively. So far 275924 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 381.75 on 15-Sep-2014 and a 52 week low of Rs. 151.50 on 29-Jan-2015.

Last one week high and low of the scrip stood at Rs. 189.75 and Rs. 161.90 respectively. The current market cap of the company is Rs. 208.24 crore.

The promoters holding in the company stood at 31.97 % while Institutions and Non-Institutions held 8.25 % and 59.78 % respectively.

Venus Remedies has received product patent grant from Indian Patent Office (IPO) for its unique research product, Vancoplus. It is valid till 2025. Vancoplus is a novel antibiotic adjuvant entity highly effective against notorious (MRSA) strain and multi-drug resistant microbes primarily responsible for causing infections such as Meningitis, Pneumonia, Typhoid, Septicemia, Urinary Tract Infection, Skin infections and Staphylococcal Endocarditis. It is also active against different mechanisms of resistance such as cell membrane impermeability, efflux pumps, biofilms, which no other existing therapeutic options available in the market are able to address.

It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product. It is one the best and safest option to address MRSA, VISA, hGISA and mixed bacterial infections of gram negative & gram positive pathogens. The total market size of MRSA in the world accounts for $ 9 billion. At present, it is growing with CAGR of 4.8 per cent which is estimated to reach to 12.4 per cent by 2017. In India, Vancoplus would have an addressable market of Rs. 214 crore by 2018-19.

Vancoplus has already been launched in the Indian market and till date approx 80,000 patients have been cured with it. It has received an overwhelming response from the medical fraternity in India. The company has conducted clinical trials on large patient population to prove the clinical efficacy and safety, which is further validated by publications in peer reviewed journals. Venus has more than 15 papers on this product.

Venus Remedies Share Price

738.90 -22.60 (-2.97%)
06-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1694.70
Dr. Reddys Lab 1241.15
Cipla 1330.80
Zydus Lifesciences 887.85
Lupin 2168.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×